PFIZER INC.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
A Study in Healthy Volunteers to Assess Immune Response to Multiple Injections of Filgrastim Hospira or Neupogen Reference Product.
- Conditions
- Healthy Volunteers
- Interventions
- Biological: Filgrastim HospiraBiological: US-Approved Neupogen
- First Posted Date
- 2016-10-05
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 256
- Registration Number
- NCT02923791
- Locations
- 🇺🇸
SeaView Research, Inc., Miami, Florida, United States
🇺🇸Seaview Jacksonville LLC, Jacksonville, Florida, United States
Open-Label Extension and Safety Study of Talazoparib
- First Posted Date
- 2016-10-03
- Last Posted Date
- 2022-08-24
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 120
- Registration Number
- NCT02921919
- Locations
- 🇺🇸
UCLA Hematology/Oncology - Burbank, Burbank, California, United States
🇺🇸TRIO-US Central Administration, Los Angeles, California, United States
🇺🇸UCLA Hematology/Oncology, Los Angeles, California, United States
A Safety And Efficacy Study of Ibuprofen 250 mg / Acetaminophen 500 mg In The Treatment Of Post-Surgical Dental Pain
- Conditions
- Post-surgical Pain Following Extraction of Molar Teeth
- Interventions
- First Posted Date
- 2016-09-23
- Last Posted Date
- 2017-08-30
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 568
- Registration Number
- NCT02912650
- Locations
- 🇺🇸
Jean Brown Research, Salt Lake City, Utah, United States
An Open-label Extension Study To Evaluate Safety Of PF-06252616 In Boys With Duchenne Muscular Dystrophy
- Conditions
- Duchenne Muscular Dystrophy
- Interventions
- Biological: PF-06252616
- First Posted Date
- 2016-09-20
- Last Posted Date
- 2020-11-23
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 59
- Registration Number
- NCT02907619
- Locations
- 🇨🇦
Alberta Children's Hospital, Calgary, Alberta, Canada
🇨🇦CHU Sainte-Justine, Montreal, Quebec, Canada
🇯🇵National Center of Neurology and Psychiatry, Kodaira, Tokyo, Japan
Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides
- Conditions
- MelanomaMerkel-cell CarcinomaBreast CarcinomaSquamous Cell CarcinomaSolid TumorsMycosis FungoidesHuman Papillomavirus-Related Malignant NeoplasmSoft Tissue Sarcoma
- Interventions
- Other: TTI-621 + T-VecDrug: TTI-621 MonotherapyOther: TTI-621 + radiationDrug: TTI-621 + PD-1/PD-L1 InhibitorDrug: TTI-621 + pegylated interferon-α2a
- First Posted Date
- 2016-09-07
- Last Posted Date
- 2023-04-05
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 56
- Registration Number
- NCT02890368
- Locations
- 🇺🇸
University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
🇺🇸University of Washington - Seattle Cancer Care Alliance, Seattle, Washington, United States
🇺🇸City of Hope National Medical Center, Duarte, California, United States
An Open-Label, 2 Treatment Period,Study To Study The Drug Interaction Between Repeated Doses Of Itraconazole And Single Dose Pharmacokinetics (PK) Of PF-06648671 In Healthy Adults.
- First Posted Date
- 2016-08-30
- Last Posted Date
- 2016-12-20
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 12
- Registration Number
- NCT02883114
- Locations
- 🇺🇸
Pfizer New Haven Clinical Research Unit, New Haven, Connecticut, United States
A Study of ARRY-382 in Combination With Pembrolizumab for the Treatment of Patients With Advanced Solid Tumors
- First Posted Date
- 2016-08-26
- Last Posted Date
- 2022-06-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 82
- Registration Number
- NCT02880371
- Locations
- 🇺🇸
Ronald Reagan UCLA Medical Center, Los Angeles, California, United States
🇺🇸UCLA Hematology/Oncology - Santa Monica, Santa Monica, California, United States
🇺🇸UCLA Hematology/Oncology, Los Angeles, California, United States
Single Dose, Repeated Dose, and Conditional Food Effect Study of PF-05221304 in Healthy Subjects
- First Posted Date
- 2016-08-18
- Last Posted Date
- 2018-05-24
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 96
- Registration Number
- NCT02871037
- Locations
- 🇺🇸
New Haven Clinical Research Unit, New Haven, Connecticut, United States
A Dental Pain Study Comparing The Analgesic Efficacy Of Ibuprofen/Caffeine
- First Posted Date
- 2016-08-11
- Last Posted Date
- 2019-04-08
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 374
- Registration Number
- NCT02863575
- Locations
- 🇺🇸
Jean Brown Research, Salt Lake City, Utah, United States
A Multiple Dose Safety And Pharmacokinetic (PK) Study Of PF-06427878 In Overweight-Obese, Otherwise Healthy Subjects
- First Posted Date
- 2016-08-04
- Last Posted Date
- 2017-05-04
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 24
- Registration Number
- NCT02855177
- Locations
- 🇺🇸
California Clinical Trials Medical Group, Glendale, California, United States
🇺🇸Qps-Mra, Llc, South Miami, Florida, United States